Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors.

Abstract

OBJECTIVE:

Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy.

METHODS:

In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups.

RESULTS:

The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose.

CONCLUSIONS:

These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.

• Authors: Michalis Liontos, Evangelos Terpos, Christos Markellos, Flora Zagouri, Alexandros Briasoulis, Ioanna Katsiana, Efthymia Skafida, Oraianthi Fiste, Elena Kunadis, Angeliki Andrikopoulou, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P Trougakos, Meletios-Athanasios Dimopoulos
• Journal: Vaccines (Vaccines (Basel)) Vol. 9 Issue 10 (Oct 08 2021) ISSN: 2076-393X [Print] Switzerland
• PMID: 34696256 (Publication Type: Journal Article)